Abstract
Senescent cells show a series of alterations, including a flat and enlarged morphology, increase in nonspecific acidic β- galactosidase activity, chromatin condensation, and changes in gene expression patterns. The onset and maintenance of senescence are regulated by two tumor suppressor proteins, p53 and Rb, whose expression is controlled by two distinct proteins, p19Arf and p16Ink4a, respectively, which are encoded by the cdkn2a locus. Transcription factor Jun dimerization protein 2 (JDP2) which binds directly to histones and DNA, inhibits the acetylation and methylation of core histones and of reconstituted nucleosomes that contain JDP2-recognition DNA sequences. JDP2-deficient mouse embryonic fibroblasts are known to be resistant to replicative senescence. Oxygen induces the expression of the JDP2 gene and JDP2 then inhibits the recruitment of polycomb repressive complexes (PRCs1 and 2) to the promoter of the gene encoding p16Ink4a, resulting in the inhibition of methylation of lysine 27 of histone H3. These findings suggest that chromatinremodeling factors, including the PRC complex controlled by JDP2, are important players in the senescence. The newly defined mechanisms that underlie the action of oxygen in the induction of JDP2 and cellular senescence are reviewed.
Keywords: JDP2, AP-1, oxidative stress, senescence, epigenetic control, p16Ink4a, p19Arf, mutations, apoptosis, nucleophosmin
Current Pharmaceutical Design
Title: Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence
Volume: 17 Issue: 22
Author(s): Shin-Wei Wang, Jiag-Ki Lee, Chia-Chen Ku, Shyh-Shin Chiou, Chen-Lung Steve Lin, Ming-Feng Ho, Deng-Chyang Wu and Kazunari K. Yokoyama
Affiliation:
Keywords: JDP2, AP-1, oxidative stress, senescence, epigenetic control, p16Ink4a, p19Arf, mutations, apoptosis, nucleophosmin
Abstract: Senescent cells show a series of alterations, including a flat and enlarged morphology, increase in nonspecific acidic β- galactosidase activity, chromatin condensation, and changes in gene expression patterns. The onset and maintenance of senescence are regulated by two tumor suppressor proteins, p53 and Rb, whose expression is controlled by two distinct proteins, p19Arf and p16Ink4a, respectively, which are encoded by the cdkn2a locus. Transcription factor Jun dimerization protein 2 (JDP2) which binds directly to histones and DNA, inhibits the acetylation and methylation of core histones and of reconstituted nucleosomes that contain JDP2-recognition DNA sequences. JDP2-deficient mouse embryonic fibroblasts are known to be resistant to replicative senescence. Oxygen induces the expression of the JDP2 gene and JDP2 then inhibits the recruitment of polycomb repressive complexes (PRCs1 and 2) to the promoter of the gene encoding p16Ink4a, resulting in the inhibition of methylation of lysine 27 of histone H3. These findings suggest that chromatinremodeling factors, including the PRC complex controlled by JDP2, are important players in the senescence. The newly defined mechanisms that underlie the action of oxygen in the induction of JDP2 and cellular senescence are reviewed.
Export Options
About this article
Cite this article as:
Wang Shin-Wei, Lee Jiag-Ki, Ku Chia-Chen, Chiou Shyh-Shin, Steve Lin Chen-Lung, Ho Ming-Feng, Wu Deng-Chyang and K. Yokoyama Kazunari, Jun Dimerization Protein 2 in Oxygen Restriction; Control of Senescence, Current Pharmaceutical Design 2011; 17 (22) . https://dx.doi.org/10.2174/138161211797052394
DOI https://dx.doi.org/10.2174/138161211797052394 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of Rimonabant: Clinical Implications
Current Pharmaceutical Design Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Antineoplastic Chemotherapy Induced QTc Prolongation
Current Drug Safety Novel Peptides: An Alternative Approach for the Treatment of Diabetes Mellitus
Current Drug Therapy Cardiac Imaging in Heart Failure with Comorbidities
Current Cardiology Reviews Enhanced Antioxidant and Protective Activities on Retinal Ganglion Cells of Carotenoids-Overexpressing Transgenic Carrot
Current Drug Targets Evaluation of Echocardiographic Abnormalities in HIV Positive Patients Treated with Antiretroviral Medications
Infectious Disorders - Drug Targets Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry EDITORIAL: Validation Techniques for Therapeutic Molecules in Drug Discovery
Current Topics in Medicinal Chemistry Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Insights into Oxidative Stress: The Isoprostanes
Current Medicinal Chemistry Synthesis and Biological Interest of Structured Docosahexaenoic Acid–Containing Triacylglycerols and Phospholipids
Current Organic Chemistry Mutations of the Apolipoprotein A5 Gene with Inherited Hypertriglyceridaemia: Review of the Current Literature
Current Medicinal Chemistry The Blood-Brain Barrier in Multiple Sclerosis: microRNAs as Key Regulators
CNS & Neurological Disorders - Drug Targets Concerning Arterial Hypertension, Homocysteine and Paraoxonase-1
Current Hypertension Reviews Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA The Role of Nitric Oxide on Endothelial Function
Current Vascular Pharmacology Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury
Current Pharmaceutical Biotechnology Hypertension in the Elderly: An Evidence-based Review
Current Pharmaceutical Design P2Y12 Receptor Antagonists in Acute Coronary Syndrome: Clinical Implications of Pharmacologic and Pharmacogenetic Differences
Recent Patents on Cardiovascular Drug Discovery